Extending the Spectrum of Moyamoya Syndrome Authors: Prince Raj, T Narasimha Murty, Nitin Kumar Borkar, Charu Tiwari, Reyaz Ahmad Wani Published: 2026 ABSTRACT ABSTRACTMoyamoya syndrome (MMS) is a rare association of Moyamoya disease with underlying other disease, which mainly includes sickle cell disease and neurofibromatosis type 1 (NF1). We hereby report a case of MMS with an underlying ganglioneuroma, which has not been reported yet, and thus extend the spectrum of MMS. INTRODUCTION Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease, characterized by nonatherosclerotic progressive occlusion of the arteries of the Circle of Willis, specifically the proximal branches of intracranial internal carotid arteries (ICAs), with development of aberrant collateral or rete mirabile.[12345] Although it was first reported in 1957, it was Suzuki and Takaku in 1969 who called it Moya Moya (Japanese term for hazy/puff of smoke) based on the angiographic findings of a group of tiny vessels sprouting to bypass the occluded one.[67] The occlusion is mostly bilateral, but not always the rule, and unilateral involvement is known to occur.[3] Chronic brain hypoperfusion is the pathophysiology caused by steno-occlusive alterations surrounding the ICA bifurcation.[24] Moyamoya syndrome (MMS) is the term used to describe patients who have a vasculopathy resembling MMD in the context of another (underlying) illness.[8] These underlying conditions include cranial irradiation, sickle cell diseases, thyroid diseases, Down syndrome, neurofibromatosis type 1 (NF1), and, rarely, Turner syndrome, Noonan syndrome, and systemic lupus erythematosus.[4] CASE REPORT A 5-year-old girl presented with a sudden history of right-sided hemiparesis a month back, for which she was taken to a private hospital and was investigated. There was no other significant history. There was no history of fever, loss of consciousness, vomiting, seizure, or headache. There was no family history of sickling or stroke. On examination done at the time of admission, she was conscious, oriented, afebrile with a heart rate of 122 per minute, respiratory rate of 22 per minute, saturation of 96%, and CRT <3 s. On systemic examination, the respiratory system was unremarkable with clear breath sounds, and on Cardio vascular system examination no cardiac murmurs were detected on auscultation. Abdominal examination revealed a palpable mass in the left hypochondrium extending into the flank region. Tone decreased in the right upper and lower limbs. Power in the right upper limb and lower limb was 1/5, whereas on the left side, it was 5/5. Neurological examination revealed an extensor plantar response on the right side. The patient underwent magnetic resonance angiography (MRA) of the brain [Figures 1 and 2] MRA findings were suggestive of moyamoya disease, with acute infarcts involving the left frontal and parietal lobes, including the precentral and postcentral gyri. Initial ultrasonography (USG) of the abdomen done to evaluate a possible renal cause of hypertension and to further characterize a palpable abdominal mass, demonstrated an approximately 8 × 7 cm mass, following which CECT was performed for detailed assessment. CECT of the abdomen (Figure 3) revealed an 8 × 7 × 7 cm retroperitoneal mass on the left side, closely related to the left renal pelvis and causing minimal calyceal dilatation. Color Doppler showed a significantly attenuated right internal carotid artery. A USG-guided biopsy from the retroperitoneal mass was done, which came as ganglioneuroma. The sickling test was negative. The two-dimensional echo was normal. In view of the above findings, the child was referred to us for further management. At the time of admission, power in both the right upper limb and right lower limb (4/5) had significantly improved. The child was evaluated by both the neurosurgery and neurology departments, and in view of no active or recurrent transient ischemic attacks and almost complete recovery of right hemiparesis, conservative management was advocated. Genetic testing was recommended but not performed due to unavailability at our institution and financial constraints limiting referral to an external facility. In view of the ganglioneuroma, the child was prepared for excision. Mass was excised in toto [Figure 3] and histopathology came as ganglioneuroma [Figure 4]. In the postoperative period, the patient was doing well, the abdominal wound healed well, and there was no abdominal complaint. Hemiparesis has improved well; the patient is currently being followed up in the neurosurgery OPD for MMD and managed conservatively. Histopathology images of ganglioneuroma are currently not available. Magnetic resonance angiography of the brain was suggestive of Moyamoya disease with acute infarcts in the left frontal and parietal lobes involving precentral as well as postcentral gyri Magnetic resonance angiography of the brain was suggestive of Moyamoya disease with acute infarcts in the left frontal and parietal lobes involving precentral as well as postcentral gyri Contrast-enhanced computed tomography of the abdomen revealed an 8 cm × 7 cm × 7 cm retroperitoneal mass on the left side Intraoperative image of left side retroperitoneal mass. Close to the left renal pelvis DISCUSSION The maturation of fragile collateral vessels exhibiting a characteristic “puff of smoke” occurrence on angiography is indicative of MMD, a progressive, idiopathic, occlusive cerebrovascular disorder characterized by stenosis or obstruction of terminal portions of the ICAs and their principal branches. Moyamoya-like vasculopathy associated with an identifiable systemic disease is referred to as MMS.[89] Several systemic disorders are well-recognized in association with MMS, including sickle cell anemia, Down syndrome, thyroid disease, NF1, and effects of cranial irradiation. Ganglioneuromas are infrequent, benign tumors derived from neural crest cells, most commonly found in the posterior mediastinum and retroperitoneum, although intracranial ganglioneuromas have occasionally been reported. Unlike neuroblastomas or ganglioneuroblastomas, ganglioneuromas are slow-growing and typically nonaggressive. The association of ganglioneuroma with MMD has not been reported extensively in the literature reviewed, including the works of Phi et al. (2015) and Demartini et al. (2022). However, a potential indirect relationship can be hypothesized.[89] NF1 provides an important link between vasculopathy and neural crest-derived tumors. NF1 is associated with both intracranial and systemic vasculopathy, including moyamoya-like stenosis and occlusion.[1011] It is also well established that NF1 predisposes to neural crest tumors such as neurofibromas and ganglioneuromas. The disruption of the NF1 gene leads to abnormal activation of the RAS-RAF-MAPK and mTOR signaling pathways, which not only drive tumorigenesis but also induce abnormal vascular smooth muscle and endothelial proliferation, ultimately contributing to vasculopathy.[8] Thus, NF1 could serve as a common etiological substrate linking moyamoya vasculopathy with neural crest tumors, including ganglioneuromas. Another possible link lies in the angiogenic and immunological abnormalities implicated in MMD. Increased levels of vascular endothelial growth factor, basic fibroblast growth factor, and inflammatory mediators such as interleukin-1 β, as well as stromal cell-derived factor-1, are detected in MMD patients.[9] Such proangiogenic and inflammatory environments may potentially influence the growth or behavior of neural crest-derived tumors like ganglioneuromas. While direct evidence is lacking, the overlapping mechanisms of vascular dysregulation and tumor biology provide a plausible biological connection. Radiation-induced vasculopathy is another relevant factor. Patients who undergo cranial irradiation for tumors like craniopharyngiomas or optic gliomas are at elevated risk for developing moyamoya-like vasculopathy.[812] Although ganglioneuromas are typically managed surgically without radiotherapy, in cases where radiation is used for other coexisting tumors in NF1 patients, the combined risks may synergistically increase the likelihood of MMS. Clinically, the coexistence of a ganglioneuroma and MMD or MMS could complicate diagnosis and management. Moyamoya vasculopathy predisposes patients to ischemic or hemorrhagic stroke, while ganglioneuromas may exert mass effects depending on their location. Imaging with magnetic resonance imaging, MRA, and digital subtraction angiography remains the cornerstone for diagnosing MMD.[9] In patients with NF1 or other predisposing syndromes, early screening for cerebrovascular abnormalities is crucial, particularly when neurological symptoms arise. The management of MMD relies primarily on surgical revascularization strategies, like encephaloduroarteriosynangiosis or direct superficial temporal artery to middle cerebral artery bypass, which improve cerebral perfusion and reduce stroke risk.[9] The potential coexistence of MMD and ganglioneuroma underscores the importance of a multidisciplinary approach, involving neurosurgeons, neurologists, oncologists, and geneticists. While current evidence is limited, this association highlights the broader concept of MMS as a vasculopathy that may complicate or be complicated by diverse systemic and neoplastic conditions. Further research and case reports are necessary to clarify whether ganglioneuromas are truly associated with MMD or if such occurrences are coincidental. CONCLUSION Although direct evidence for the association of ganglioneuroma with MMD is lacking in the reviewed literature, there are biologically plausible mechanisms, especially in the context of NF1 and shared pathways of angiogenesis, immunological dysregulation, and vascular proliferation. Clinicians should remain vigilant for the coexistence of rare tumors such as ganglioneuroma in patients with moyamoya vasculopathy, and vice versa, as this may have significant implications for diagnosis, treatment, and long-term outcome. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.